Back to Treatments

Treatment

Bevacizumab

3
Conditions
505
Trials
75K
Participants
43%
Average Safety

Condition Evidence

Brain and central nervous system cancer

117 trials · 10K participants

55% effectiveness · 40% safety

Macular Degeneration

130 trials · 55K participants

88% effectiveness · 45% safety

Ovarian cancer

258 trials · 10K participants

70% effectiveness · 45% safety
Bevacizumab | DFDA